I think the most important issue now that the results are announced is how they move forward from here of which disappointingly there was no mention.
Are they going to use the good data from the 45+ cohort to pursue new commercial opportunities or will it be a case of great we'll be able to satisfy the new European requirements now so let's move on?
Our new CEO must use this to put it simply make money (and plenty of it)
Ann: Viraleze shows antiviral efficacy in COVID-19 patients, page-41
-
- There are more pages in this discussion • 34 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add SPL (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
10.0¢ |
Change
-0.005(4.76%) |
Mkt cap ! $41.23M | |||
| Open | High | Low | Value | Volume |
| 9.8¢ | 10.5¢ | 9.8¢ | $42.60K | 414.9K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 15000 | 10.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 10.5¢ | 92635 | 5 |
View Market Depth
| Last trade - 15.17pm 15/07/2024 (20 minute delay) ? |
| SPL (ASX) Chart |